229,000
TB incidence in 2022
62,000
drug-resistant TB incidence in 2022
24,300
deaths from TB in 2022
The Union's Offices
The Union’s headquarters in Paris is the global cornerstone of the organisation, taking on a coordinating role, sets policy and provides financial oversight of the organisation. The Union Switzerland Office, based in Geneva, acts as the political convenor for The Union, working at a strategic level to influence global health policy through high-level discussion and partnership.
The Union Headquarters in Paris
2 Rue Jean Lantier
75001 Paris
France
The Union Switzerland Office
Avenue Guiseppe Motta 31/33
1202 Geneve
Switzerland
Members of The Union Europe Region
The Union is divided into seven regions to provide a platform for addressing lung health and related issues from a regional perspective. This structure offers members opportunities to network with colleagues who face the same regional challenges and contributes to The Union's deep understanding of local issues.
The Union Europe Region is made up of individuals and organisations.

Members in Europe initiated the first dedicated region Scientific Track, held at the Union World Conference on Lung Health. The sessions, developed in partnership with members of The Union’s Europe Region, shared experiences and challenges that are specific to the continent and invited delegates to focus on TB and lung health concerns that are particularly pressing in Europe.
UNION NEWS FROM THE Europe REGION
Union DR-TB Working Group awarded grant to support nurses
Researchers at the University of Virginia, in collaboration with colleagues at the Johns Hopkins University School of Nursing, Boston…
Can we optimize the TB response amid funding constraints using evidence-based, cost-effective strategies
An article in a forthcoming issue of IJTLD OPEN examines cost-effective and integrated strategies to sustain and strengthen the TB response in low- and middle-income countries amid declining donor funding.
Laboratory strengthening strategies to advance drug susceptibility testing for BPaL regimens in TB treatment
An article in a forthcoming issue of PHA assesses efforts to strengthen drug susceptibility testing in seven countries to support BPaL rollout, highlighting variable capacity and the need for ongoing training and infrastructure.
Managing household contacts of individuals with rifampicin-resistant tuberculosis
In the last ten years, the epidemiology, diagnosis and treatment of multidrug-resistant (MDR) or rifampicin-resistant tuberculosis (RR-…